60 Degrees Pharmaceuticals Accelerates Babesiosis Trial Enrollment
Event summary
- 60 Degrees Pharmaceuticals enrolled its first seasonal patient in a clinical trial of tafenoquine for hospitalized babesiosis patients, ahead of schedule.
- The trial, conducted at five clinical sites in the Northeastern U.S., aims to enroll at least 24 patients before an interim analysis.
- Interim analysis could occur as early as July 2026, with results expected approximately 50 days post-enrollment completion.
- Tafenoquine is currently approved for malaria prophylaxis but not for babesiosis treatment.
The big picture
60 Degrees Pharmaceuticals is leveraging its existing malaria prophylaxis drug, tafenoquine, to explore new indications in vector-borne diseases. The accelerated enrollment in the babesiosis trial reflects both the urgency of addressing tick-borne illnesses, as highlighted by the CDC, and the strategic pivot toward diversifying its product portfolio beyond malaria. The success of this trial could position the company as a key player in the treatment of emerging infectious diseases.
What we're watching
- Trial Execution
- Whether the accelerated enrollment pace will sustain through the 2026 tick season and meet interim analysis timelines.
- Regulatory Pathway
- How the FDA may view tafenoquine's potential repurposing for babesiosis, given its existing approval for malaria.
- Market Opportunity
- The pace at which 60 Degrees Pharmaceuticals can expand into vector-borne disease treatments beyond malaria.
Related topics